COMPETING RISKS OF DEATH IN OLDER ADULTS WITH ADVANCED NON-SMALL CELL LUNG CANCER RECEIVING PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) INHIBITORS

被引：0
|
作者：
Kim, Y. [1 ]
Suh, H. S. [2 ]
Park, C. [1 ]
机构：
[1] Univ Texas Austin, Austin, TX USA
[2] Kyung Hee Univ, Coll Pharm, Seoul, South Korea
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO126
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [21] Molecular Epidemiology of Programmed Cell Death 1-Ligand 1 (PD-L1) Protein Expression in Non-Small Cell Lung Cancer
    Schabath, Matthew
    Dalvi, Tapashi
    Dai, Hongyue
    Crim, Alan
    Midha, Anita
    Shire, Norah
    Walker, Jill
    Greenawalt, Danielle
    Lawrence, David
    Rigas, James
    Brody, Robert
    Potter, Danielle
    Kumar, Naveen
    Huntsman, Shane
    Grays, Jhanelle
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S475 - S476
  • [22] Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis
    Liu, Yi
    Zhou, Sijing
    Du, Yongsheng
    Sun, Li
    Jiang, Huihui
    Zhang, Binbin
    Sun, Gengyun
    Wang, Ran
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4619 - 4630
  • [23] Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
    Abaza, Abdelrahman
    Idris, Faten Sid
    Shaikh, Humna Anis
    Vahora, Ilma
    Moparthi, Kiran Prasad
    Al Rushaidi, Majdah T.
    Muddam, Meghana Reddy
    Obajeun, Omobolanle A.
    Jaramillo, Arturo P.
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [24] Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
    Dehghani, Tannaz
    Shahrjerdi, Alireza
    Kahrizi, Mohammad Saeed
    Soleimani, Elnaz
    Ravandeh, Saeideh
    Merza, Muna S.
    Rahnama, Negin
    Ebrahimzadeh, Farnoosh
    Bakhshesh, Morteza
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 246
  • [25] Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors.
    Gettinger, Scott N.
    Zhang, Xuchen
    Homer, Robert
    Possick, Jennifer
    Wurtz, Anna
    Goldberg, Sarah B.
    Chiang, Anne C.
    Herbst, Roy S.
    Rubinowitz, Ami
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [26] Expression analysis of programmed cell death 1 ligand 1 (PD-L1) in patients with non-small cell lung cancer
    Peng, Nanqiu
    Qin, Liang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2022, 15 (01): : 1 - 5
  • [27] Programmed death ligand-1 expression in non-small cell lung cancer
    Velcheti, Vamsidhar
    Schalper, Kurt A.
    Carvajal, Daniel E.
    Anagnostou, Valsamo K.
    Syrigos, Konstantinos N.
    Sznol, Mario
    Herbst, Roy S.
    Gettinger, Scott N.
    Chen, Lieping
    Rimm, David L.
    LABORATORY INVESTIGATION, 2014, 94 (01) : 107 - 116
  • [28] Programmed death-1 or programmed death ligand-1 inhibitors? A meta-analysis of differential efficacy as compared to chemotherapy in advanced non-small cell lung cancer
    Bozcuk, Hakan
    Artac, Mehmet
    Mutlu, Hasan
    Sever, Ozlem
    Yildirim, Mustafa
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (02) : 405 - 413
  • [29] Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
    Justin C. Kao
    Adipong Brickshawana
    Teerin Liewluck
    Current Neurology and Neuroscience Reports, 2018, 18
  • [30] Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors
    Kao, Justin C.
    Brickshawana, Adipong
    Liewluck, Teerin
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2018, 18 (10)
12345